HC Wainwright Reaffirms “Neutral” Rating for Aadi Bioscience (NASDAQ:AADI)
HC Wainwright reaffirmed their neutral rating on shares of Aadi Bioscience (NASDAQ:AADI – Free Report) in a research report sent to investors on Tuesday, Benzinga reports. HC Wainwright also issued estimates for Aadi Bioscience’s Q2 2024 earnings at ($0.66) EPS, Q4 2024 earnings at ($0.71) EPS, FY2024 earnings at ($2.73) EPS, Q1 2025 earnings at […]
More Stories
REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of “Moderate Buy” by Analysts
REGENXBIO Inc. (NASDAQ:RGNX – Get Free Report) has been given an average rating of “Moderate Buy” by the twelve ratings...
Transocean (NYSE:RIG) PT Raised to $6.00 at Morgan Stanley
Transocean (NYSE:RIG – Get Free Report) had its price target increased by stock analysts at Morgan Stanley from $5.00 to...
Devon Energy (NYSE:DVN) Coverage Initiated at Jefferies Financial Group
Equities research analysts at Jefferies Financial Group started coverage on shares of Devon Energy (NYSE:DVN – Get Free Report) in...
Bank OZK (NASDAQ:OZKAP) Announces Quarterly Dividend of $0.29
Bank OZK (NASDAQ:OZKAP – Get Free Report) declared a quarterly dividend on Thursday, October 3rd, Wall Street Journal reports. Stockholders...
AngioDynamics (NASDAQ:ANGO) Issues FY 2025 Earnings Guidance
AngioDynamics (NASDAQ:ANGO – Get Free Report) updated its FY 2025 earnings guidance on Thursday. The company provided EPS guidance of...
RTX (NYSE:RTX) Rating Increased to Hold at Deutsche Bank Aktiengesellschaft
RTX (NYSE:RTX – Get Free Report) was upgraded by equities researchers at Deutsche Bank Aktiengesellschaft from a “sell” rating to...